Table 1 Patient characteristics

From: Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

Mean age (range) years

66.9 (41–89)

Male/female

92/32

Renal pelvic cancer

18

Ureteral cancer

20

Bladder cancer

86

 (TUR-BT/total cystectomy)

(37/49)

Histopathological grading

 

 G1

11

 G2

69

 G3

43

Pathological staging

 

 Ta

17

 T1

52

 T2

18

 T3

28

 T4

8

Mean follow up (range), months

64.3 (0–192)

  1. TUR-BT: transurethral resection of bladder tumour.
Back to article page